Search Thermo Fisher Scientific
Search Thermo Fisher Scientific
In this webinar, Thermo Fisher Scientific describe how they are mobilizing to meet rapidly growing demand for AAV vector from both technology development and manufacturing strategy viewpoints.
In this webinar, you'll learn more about the performance characteristics of a true pan-tropic AAV resin—POROS CaptureSelect AAVX
In this webinar, we share the development and validation of a new, and highly sensitive and accurate solution for detecting and quantifying residual HEK293 host cell DNA to help meet regulatory requirements.
Hear from our experts: A retrospective look at past Mycoplasma validation queries and responses
Watch this educational webinar and learn how recent innovation can help you to significantly push the boundaries of viral vectors productivity and quality.
Watch this webinar and learn more about validation of a qPCR assay for residual host cell DNA quantitation.
Learn about the unique features and advantages of our HyPerforma Single-Use Fermentor, the first single-use system specifically engineered for microbial fermentation.
This short video highlights one of our 2019 Knowledge Culture workshops on viral vector manufacturing.
A case study demonstrates that affinity chromatography can offer efficiency and scalability for gene therapy manufacturing using viral vectors.
Learn more about Capture Select technology minimizing the steps in the purification process.
The quality of raw materials needs to be considered according to the stage of development of the cell or gene therapy.
In moving processes from bench to pilot and ultimately production fermentors, it is critical to have a reliable scaledown model.
Enabling advancement of gene therapies in the clinic.
The manufacturing of plasmid DNA is becoming a supply bottleneck due to rapidly growing demand for various gene-targeting biotherapeutics.
Find out more about the development of a novel residual DNA assay for HEK-293.
This article focuses on key regulatory considerations and requirements across the cell and gene therapy raw and starting materials area.
Adherent cell cultures, such as those with Vero cells, are often more challenging than their suspension-based counterparts.
With the advancement of gene delivery vectors and gene editing technologies, cell and gene therapies are a very real solution to many previously untreatable or difficult to treat diseases
Access a targeted collection of scientific application notes, case studies, posters, white papers and more for bioprocessing: